Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

$3 billion FUJIFILM deal will nearly double Regeneron’s large-scale U.S. biologics manufacturing capacity over the next decade. Regeneron adds 7,000+ U.S. jobs in five years, with $7B+ in ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Regeneron Pharmaceuticals, Inc.'s stock has dropped 30% since July due to concerns around Eylea's declining market share in the face of competition from generics and Roche's Vabysmo. Dupixent's ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.6% after a judge denied the company's motion for a preliminary injunction to block an Amgen (AMGN) biosimilar version of Regeneron's blockbuster ...

Every hero has an origin story. For Atreya Manaswi, it started a few summers ago. He was out on a lake with a friend and his grandfather, a beekeeper. The older man was describing the dramatic ...

Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver, the companies ...

Regeneron is joining its pharma peers in the venture investing sector, committing up to $500 million over the next five years for its new private financing arm. The New York pharma unveiled ...

EAST GREENBUSH — Drugmaker Regeneron Pharmaceuticals, which employs more than 3,000 people in Rensselaer County, is being accused by the federal government of illegally inflating Medicare ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Regeneron shares were lower ahead of the opening bell Thursday morning after the DOJ ...